FIBRISTAL Trademark

Trademark Overview


On Thursday, April 20, 2017, a trademark application was filed for FIBRISTAL with the United States Patent and Trademark Office. The USPTO has given the FIBRISTAL trademark a serial number of 87418777. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Wednesday, October 10, 2018. This trademark is owned by Allergan Finance, LLC. The FIBRISTAL trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the ...
fibristal

General Information


Serial Number87418777
Word MarkFIBRISTAL
Filing DateThursday, April 20, 2017
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateWednesday, October 10, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, September 5, 2017

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of the word "FIBRISTAL" in lower case letters, with portions of three leaves extending generally upwards from the top of the letter "B".
Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; pharmaceutical preparations, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and pharmaceutical gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and medicated creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateWednesday, October 10, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Finance, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressParsippany, NJ 07054

Party NameAllergan Finance, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Wednesday, October 10, 2018ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Wednesday, October 10, 2018ABANDONMENT - AFTER PUBLICATION
Tuesday, October 9, 2018TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, October 9, 2018ITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST
Thursday, October 4, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 27, 2018TEAS EXTENSION RECEIVED
Wednesday, March 28, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 26, 2018EXTENSION 1 GRANTED
Monday, March 26, 2018EXTENSION 1 FILED
Monday, March 26, 2018TEAS EXTENSION RECEIVED
Tuesday, October 31, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 5, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 5, 2017PUBLISHED FOR OPPOSITION
Wednesday, August 16, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 18, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 17, 2017EXAMINER'S AMENDMENT ENTERED
Monday, July 17, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, July 17, 2017EXAMINERS AMENDMENT E-MAILED
Monday, July 17, 2017EXAMINERS AMENDMENT -WRITTEN
Monday, July 17, 2017ASSIGNED TO EXAMINER
Thursday, April 27, 2017NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, April 26, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, April 24, 2017NEW APPLICATION ENTERED IN TRAM